Pulse Biosciences (PLSE) surged over 44% Friday to $19.81 following the release of positive late-breaking clinical data for its nPulse™ Cardiac Catheter System. The stock reached a day high of $20.28, marking a massive reversal for the medical device company whose shares were down nearly 22% over the last 12 months.
| Current Price | $19.81 |
| Daily Change | +44.70% 🟢 |
| Day High | $20.28 |
| Day Low | $15.50 |
| 52-Week Range | $12.56 – $24.70 |
The rally was ignited by results from a first-in-human feasibility study for treating atrial fibrillation, which were presented at the 2026 AF Symposium in Boston. According to Investing.com, the clinical breakthrough was complemented by a bullish initiation from Mizuho, which set a price target suggesting significant further upside.
Trading volume for the session exploded to approximately 1.68 million shares. This represents a substantial spike compared to the company’s average daily volume of roughly 183,000 shares.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | +26.38% | 🟢 |
| 3 Months | +18.07% | 🟢 |
| 6 Months | +30.50% | 🟢 |
| 1 Year | -21.78% | 🔴 |
Key Takeaways
- PLSE stock jumped over 44% today to close near its 52-week high.
- The nPulse™ Cardiac Catheter System achieved 100% procedural success at 6 months.
- Mizuho initiated coverage with an Outperform rating and a $30.00 price target.
- Clinical data showed a low 1.3% serious adverse event rate across 150 patients.
- The company scheduled its full-year 2025 financial results call for February 19, 2026.
What Triggered Pulse Biosciences (PLSE) Stock's Massive Surge Today?
The primary driver behind today’s surge was the presentation of clinical data validating the company’s Nanosecond Pulsed Field Ablation (nsPFA) technology. Investors responded to the high durability and safety profile of the nPulse™ system, reflecting the core principles of what makes stocks go up and down.
Adding fuel to the rally, Mizuho initiated coverage with an Outperform rating and a $25.00 price target, which represented a 75% upside from the previous trading range. MarketBeat reports that Mizuho also issued a higher price target of $30.00 during the session, further boosting investor confidence as the stock gapped up from its $13.69 previous close.
Positive Clinical Data Unveiled for nPulse™ Cardiac Catheter System
Data presented at the AF Symposium involving 150 patients demonstrated that the nPulse™ system achieved 100% procedural success in evaluable patients at 6 months. This success rate remained high at 96% during the 12-month follow-up.
Dr. Vivek Reddy of Mount Sinai Fuster Heart Hospital stated the system has the ability to “considerably advance” the treatment of atrial fibrillation. The study also highlighted procedural efficiencies, with total procedure times averaging 65 minutes.
Safety metrics were equally strong, reporting a serious adverse event rate of just 1.3%. Pulse Biosciences CEO Paul LaViolette described these findings as an important milestone that validates the safety and speed benefits of the nsPFA technology.
How Are Analysts Reacting to PLSE's Breakthrough?
Analyst sentiment has shifted toward optimism following the clinical update, though some caution remains. Utilizing best stock analysis apps can help investors track these shifting price targets and ratings.
Mizuho’s bullish stance is based on a risk-adjusted analysis that allocates $17 per share specifically to the company’s PFA technology. The firm anticipates rapid adoption of the system following future regulatory clearances.
Other firms maintain more conservative targets. HC Wainwright reiterated a Buy rating with a $15.00 target, while Oppenheimer analyst Suraj Kalia called the results “encouraging” but noted they need to be proven in further studies.
Oppenheimer currently maintains a $6.00 price target, highlighting the wide range of valuations currently assigned to the clinical-stage company.
PLSE's Financials and Market Position: A Quick Look
While the clinical data is the main focus, Pulse Biosciences has shown improvement in recent financial reports. On November 5, 2025, the company reported a quarterly loss of $0.29 per share, beating the consensus estimate of $0.31.
However, Q1 2024 revenue of $3.83 million fell short of the $4.30 million analysts had expected. The company maintains a strong liquidity position with a current ratio of 10.02, though it remains unprofitable with a net income of -$74.73 million.
Institutional ownership currently stands at about 33%, with firms like Geode Capital Management and Portolan Capital Management holding positions.
| Company | Symbol | Daily Change | Market Cap |
|---|---|---|---|
| Pulse Biosciences | PLSE | +44.70% | – |
| Intuitive Surgical | ISRG | +2.55% | – |
| SI-BONE | SIBN | -1.02% | – |
| TransMedics Group | TMDX | +3.21% | – |
| Alphatec Holdings | ATEC | +2.74% | – |
| Medtronic | MDT | -0.55% | – |
| Industry Avg | – | +1.51% | – |
Bull vs. Bear: Weighing PLSE's Risks and Rewards
The bull case for PLSE centers on its “best-in-class” clinical results. Dr. David Kenigsberg noted that in a field where a 20% to 25% recurrence rate is expected, PLSE's 4% recurrence rate at 12 months significantly exceeds expectations.
Bulls argue that the proprietary Tissue NanoPoration platform provides a competitive advantage that could lead to rapid market share gains. Conversely, the bear case is rooted in financial risk and market skepticism.
Short interest was recently recorded at over 10%, highlighting the inherent risks of short selling for those betting against the stock's long-term sustainability. Critics also point to the negative EPS growth of -6.5% and the fact that the company still requires a pivotal IDE study for full regulatory approval and commercialization.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • 100% clinical success rate at 6 months | • Reported net loss of -$74.73M |
| • Mizuho price target of $30.00 | • High short interest (10.3%) |
| • Strong liquidity (Current Ratio: 10.02) | • Negative EPS growth of -6.5% |
What Should Investors Watch Next for Pulse Biosciences?
The next major catalyst for Pulse Biosciences will be its fourth-quarter and full-year 2025 conference call, scheduled for February 19, 2026. This call is expected to provide deeper insights into the company’s strategic direction and its progress toward initiating a pivotal IDE study.
As the company moves from feasibility studies toward commercialization, understanding how to read stock charts will be helpful for investors monitoring the stock's ability to maintain its current momentum. Any news regarding the regulatory path for the nPulse™ system or the CellFX® System will likely dictate the stock's future direction.
The Bottom Line
Pulse Biosciences has successfully transitioned from a speculative clinical-stage firm to a high-potential contender in the electrophysiology market. While today's 44% surge is a major win for shareholders, the company must now prove it can convert positive feasibility data into long-term commercial success and profitability.
Presenting a balanced outlook, the upcoming February 19 earnings call will be the next critical test for the stock's rally.
